Achillion Pharmaceuticals reports that Joel Barrish, Ph.D., has been named the Company’s Chief Scientific Officer and Executive Vice President, effective January 4, 2016. Dr. Barrish joins Achillion with more than 30 years of experience in the pharmaceutical industry. For the last five years, Dr. Barrish was Vice President and Head of Discovery Chemistry at Bristol-Myers Squibb, leading chemical research on small molecules and other modalities across all therapeutic areas and sites … more

Earlier Achillion announced the appointment of Frank Verwiel, M.D., former President and Chief Executive Officer of Aptalis Pharma, to Achillion’s Board of Directors. With more than 25 years of experience in the pharmaceutical industry, Dr. Verwiel was most recently President, Chief Executive Officer and Board member of Aptalis Pharma. Prior to its acquisition in 2014 by Forest Laboratories, Aptalis manufactured, marketed and distributed a broad line of specialty pharmaceutical products and services used in the treatment of cystic fibrosis and gastrointestinal disorders … more